晚期尿路上皮癌循环肿瘤DNA改变及其与临床结局的关联:一项先导研究
该先导研究对124例晚期尿路上皮癌患者行73基因cfDNA检测,90.3%检出至少一种基因改变,BRCA1和RAF1改变与更差的总生存和无失败生存相关,支持进一步评估DNA损伤反应和RAF激酶抑制剂。
要点
- 124例晚期尿路上皮癌患者中90.3%检出至少一种cfDNA基因改变,每样本中位改变数为4。
- BRCA1改变与更差的总生存(HR 2.48;p=0.07)和无失败生存(HR 2.35;p=0.016)相关。
- RAF1改变与更差的总生存(HR 4.87;p=0.007)和无失败生存(HR 2.40;p=0.047)相关。
核心结论
- 大多数晚期尿路上皮癌患者可检出cfDNA分子改变,BRCA1和RAF1改变为不良预后因素,支持进一步评估DNA损伤反应和RAF激酶抑制剂。
研究设计与样本
- 先导研究,纳入124例接受cfDNA分析(Guardant360 73基因测序面板)的晚期尿路上皮癌患者,采用Kaplan-Meier法和Cox比例风险回归评估分子改变及临床因素与总生存和无失败生存的关联。
主要发现
- 中位年龄72岁,65例(52.4%)既往接受铂类治疗,21例(17.1%)接受紫杉烷类治疗,10例(8.1%)接受PD-1/PD-L1抑制剂治疗。
- 112例(90.3%)检出至少一种基因组改变,每样本中位改变数为4(范围0-80)。
- 常见改变基因包括TP53(54.8%)、PIK3CA(24.2%)、ARID1A(22.6%)、ERBB2(19.4%)、EGFR(16.1%)、NF1(13.7%)、RB1(12.9%)、FGFR3(11.3%)、BRAF(10.5%)、BRCA1(10.5%)和RAF1(8.9%)。
- BRCA1改变与更差的总生存(HR 2.48;p=0.07)和无失败生存(HR 2.35;p=0.016)相关,RAF1改变与更差的总生存(HR 4.87;p=0.007)和无失败生存(HR 2.40;p=0.047)相关。
- 较差的东部肿瘤协作组体能状态和存在内脏转移与更短的总生存相关,并观察到基因组演化。
临床怎么用
- 作者认为BRCA1和RAF1改变为不良预后因素,支持进一步评估DNA损伤反应和RAF激酶抑制剂。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cell-free circulating DNA (cfDNA) can be used for noninvasive profiling of tumor genomic aberrations. We hypothesized that molecular alterations may inform prognostication in advanced urothelial carcinoma (aUC). We evaluated 124 aUC patients who underwent cfDNA analysis using a 73-gene sequencing panel (Guardant360). The association of molecular alterations and clinical factors with overall survival (OS) and failure-free-survival (FFS) was evaluated using the Kaplan-Meier method and Cox proportional-hazards regression. The median age was 72yr, and 65 patients (52.4%) received prior therapy with platinum, 21 (17.1%) with a taxane, and ten (8.1%) with a PD-1/PD-L1 inhibitor. At least one genomic alteration was detected in 112 patients (90.3%). The median number of alterations per sample was four (range 0-80). Commonly altered genes included TP53 (54.8%), PIK3CA (24.2%), ARID1A (22.6%), ERBB2 (19.4%), EGFR (16.1%), NF1 (13.7%), RB1 (12.9%), FGFR3 (11.3%), BRAF (10.5%), BRCA1 (10.5%), and RAF1 (8.9%). BRCA1 and RAF1 alterations were associated with worse OS (hazard ratio [HR] 2.48; p=0.07; HR 4.87; p=0.007) and FFS (HR 2.35; p=0.016; HR 2.40; p=0.047). Poor Eastern Cooperative Oncology Group performance status and the presence of visceral metastasis were associated with shorter OS; genomic evolution was observed. In conclusion, cfDNA molecular alterations were detected in most aUC patients. BRCA1 and RAF1 alterations were negatively prognostic, supporting further evaluation of DNA damage response and RAF kinase inhibitors. PATIENT SUMMARY: Noninvasive testing of cell-free circulating DNA in advanced urothelial carcinoma identifies clinically relevant molecular aberrations. Alterations in BRCA1 and RAF1 genes appear to be negatively associated with clinical outcomes, supporting further study of DNA damage response and RAF kinase inhibitors in selected patients.
引用
- Grivas P, Lalani AA, Pond GR, et al. Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. Eur Urol Oncol. 2019. PMID: 31412004. doi:10.1016/j.euo.2019.02.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。